Oncotarget:2型糖尿病患者嗅觉障碍新认知

2016-01-25 佚名 生物谷

根据一项最近发表于Oncotarget期刊的新研究,瑞典卡罗林斯卡学院(Karolinska Institutet)研究人员在2型糖尿病大鼠模型中识别出特定神经细胞中的改变。由于这些神经细胞对气味识别很重要,因此新的发现或许可以解释为什么2型糖尿病患者经常出现嗅觉问题,同时可能开启新的研究领域,为对抗2型糖尿病患者中的神经退行性疾病开发预防性疗法。 众所周知的是,2型糖尿病患者经常遭受神经退行性

根据一项最近发表于Oncotarget期刊的新研究,瑞典卡罗林斯卡学院(Karolinska Institutet)研究人员在2型糖尿病大鼠模型中识别出特定神经细胞中的改变。由于这些神经细胞对气味识别很重要,因此新的发现或许可以解释为什么2型糖尿病患者经常出现嗅觉问题,同时可能开启新的研究领域,为对抗2型糖尿病患者中的神经退行性疾病开发预防性疗法。

众所周知的是,2型糖尿病患者经常遭受神经退行性疾病比如阿尔茨海默病的侵袭。这些神经退行性疾病的一个早期症状是气味识别能力的下降。这种嗅觉问题也经常出现在2型糖尿病患者中,暗示嗅觉下降可能与神经退行性疾病的发展相关联。然而,截至目前,2型糖尿病中负责这些嗅觉问题的神经细胞一直没有被充分认识。

在新的研究中,卡罗林斯卡学院的研究人员在2型糖尿病大鼠的梨状皮层中识别出中间神经元中的改变。梨状皮层是大脑的一个区域,在气味的识别和编码中扮演着至关重要的角色。研究人员还表明,所识别的神经改变可以被临床使用的抗糖尿病药物胰升血糖素样肽1(glucagon-like peptide 1)在药理学上抵消。

"在2型糖尿病人群中,神经退行性疾病的发病率较高"该研究作者之一Grazyna Lietzau说,"我们认为,这些发现对于开发预防性药物疗法来对抗这些患者中的阿尔茨海默病和帕金森病可能是重要的。"

原始出处:

Grazyna Lietzau, Thomas Nyström,Claes-Göran Östenson,et al, Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist Exendin-4.Oncotarget.2015


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636407, encodeId=d48c163640e80, content=<a href='/topic/show?id=9e2f4020896' target=_blank style='color:#2F92EE;'>#嗅觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40208, encryptionId=9e2f4020896, topicName=嗅觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da422628224, createdName=ms9833124466084992, createdTime=Tue Jun 21 20:03:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795323, encodeId=dad21e9532393, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 22 18:03:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60833, encodeId=de026083336, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60834, encodeId=f12d6083407, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60835, encodeId=f82a608356e, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383205, encodeId=d7b71383205af, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Jan 27 09:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473949, encodeId=72d814e3949b8, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jan 27 09:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636407, encodeId=d48c163640e80, content=<a href='/topic/show?id=9e2f4020896' target=_blank style='color:#2F92EE;'>#嗅觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40208, encryptionId=9e2f4020896, topicName=嗅觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da422628224, createdName=ms9833124466084992, createdTime=Tue Jun 21 20:03:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795323, encodeId=dad21e9532393, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 22 18:03:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60833, encodeId=de026083336, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60834, encodeId=f12d6083407, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60835, encodeId=f82a608356e, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383205, encodeId=d7b71383205af, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Jan 27 09:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473949, encodeId=72d814e3949b8, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jan 27 09:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-12-22 闆锋旦
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636407, encodeId=d48c163640e80, content=<a href='/topic/show?id=9e2f4020896' target=_blank style='color:#2F92EE;'>#嗅觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40208, encryptionId=9e2f4020896, topicName=嗅觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da422628224, createdName=ms9833124466084992, createdTime=Tue Jun 21 20:03:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795323, encodeId=dad21e9532393, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 22 18:03:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60833, encodeId=de026083336, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60834, encodeId=f12d6083407, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60835, encodeId=f82a608356e, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383205, encodeId=d7b71383205af, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Jan 27 09:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473949, encodeId=72d814e3949b8, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jan 27 09:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-27 李继凯

    有深度

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1636407, encodeId=d48c163640e80, content=<a href='/topic/show?id=9e2f4020896' target=_blank style='color:#2F92EE;'>#嗅觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40208, encryptionId=9e2f4020896, topicName=嗅觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da422628224, createdName=ms9833124466084992, createdTime=Tue Jun 21 20:03:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795323, encodeId=dad21e9532393, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 22 18:03:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60833, encodeId=de026083336, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60834, encodeId=f12d6083407, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60835, encodeId=f82a608356e, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383205, encodeId=d7b71383205af, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Jan 27 09:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473949, encodeId=72d814e3949b8, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jan 27 09:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-27 李继凯

    值得学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1636407, encodeId=d48c163640e80, content=<a href='/topic/show?id=9e2f4020896' target=_blank style='color:#2F92EE;'>#嗅觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40208, encryptionId=9e2f4020896, topicName=嗅觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da422628224, createdName=ms9833124466084992, createdTime=Tue Jun 21 20:03:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795323, encodeId=dad21e9532393, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 22 18:03:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60833, encodeId=de026083336, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60834, encodeId=f12d6083407, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60835, encodeId=f82a608356e, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383205, encodeId=d7b71383205af, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Jan 27 09:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473949, encodeId=72d814e3949b8, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jan 27 09:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
    2016-01-27 李继凯

    收藏

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1636407, encodeId=d48c163640e80, content=<a href='/topic/show?id=9e2f4020896' target=_blank style='color:#2F92EE;'>#嗅觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40208, encryptionId=9e2f4020896, topicName=嗅觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da422628224, createdName=ms9833124466084992, createdTime=Tue Jun 21 20:03:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795323, encodeId=dad21e9532393, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 22 18:03:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60833, encodeId=de026083336, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60834, encodeId=f12d6083407, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60835, encodeId=f82a608356e, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383205, encodeId=d7b71383205af, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Jan 27 09:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473949, encodeId=72d814e3949b8, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jan 27 09:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1636407, encodeId=d48c163640e80, content=<a href='/topic/show?id=9e2f4020896' target=_blank style='color:#2F92EE;'>#嗅觉障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40208, encryptionId=9e2f4020896, topicName=嗅觉障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9da422628224, createdName=ms9833124466084992, createdTime=Tue Jun 21 20:03:00 CST 2016, time=2016-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795323, encodeId=dad21e9532393, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Thu Dec 22 18:03:00 CST 2016, time=2016-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60833, encodeId=de026083336, content=有深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60834, encodeId=f12d6083407, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=60835, encodeId=f82a608356e, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 13:01:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383205, encodeId=d7b71383205af, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Jan 27 09:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473949, encodeId=72d814e3949b8, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Jan 27 09:03:00 CST 2016, time=2016-01-27, status=1, ipAttribution=)]

相关资讯

Lancet Dia& Endo:2型糖尿病患者,降糖联合降压治疗——试试10mg达帕格列净

高血压是2型糖尿病患者的常见合并症,也是微血管和大血管疾病的主要危险因素。虽然钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂的降血压效果已经建立,但是还需要给予使用这些药物接受抗高血压治疗的患者指导如何如何应用这些药物。该研究的目的是比较SGLT2抑制剂达帕格列净和安慰剂对于不充分控制的2型糖尿病和高血压患者的血压和血糖效果。在这项双盲,安慰剂对照,3期研究中,参与者来自五大洲16个国家311个中心

NEJM:依帕列净可降低2型糖尿病患者心血管事件和死亡的发生率

依帕列净(新型钠葡萄糖协同转运蛋白2抑制剂)的服用对有高危心血管疾病风险的2型糖尿病患者发生心血管发病率和死亡率是未知的。

BMJ:2型糖尿病患者HbA1c的检测及治疗是否过度?

此回顾性分析了来自2001-2013年的国家行政索赔数据库,包括商业保险参保人员的数据。共纳入了31545名年龄≥18岁(平均年龄58岁)的2型糖尿病患者,血糖控制良好(24个月以内,两次连续测试显示HbA1c<7.0%,平均HbA1c为6.2%),并未使用胰岛素,也无严重低血糖或高血糖史,女性不处于妊娠期。

BMJ:二甲双胍——2型糖尿病治疗的一线药物:are we sure?

目前推荐二甲双胍作为2型糖尿病治疗的一线降糖药物。该建议是基于英国1998年发表的一项前瞻性糖尿病研究(UKPDS 34)结果。该研究发现,患者使用二甲双胍后,其10年全因死亡率(相对风险0.64,95% CI,0.45-0.91)以及心肌梗塞(相对风险0.61,95% CI,0.41-0.89)的发生率有所降低。为避免一人死亡而需治疗的人数为14,且绝对风险降低0.07。然而,这些结果却是在一个

Diabetes Care:2型糖尿病减肥期间胰腺内三酰甘油的相关研究

研究者进行了一项研究,探究2型糖尿病患者减肥期间胰腺三酰甘油的下降能否作为全身脂肪或特定糖尿病的简单反射,同时是否与恢复胰岛素分泌功能有关。研究组纳入了进行了胃旁路手术的2型糖尿病患者(T2DM),按年龄、体重、性别等匹配了糖耐量正常的人群 (NGT)。 研究者使用同相和不同相的磁共振成像监测胰腺和肝脏三酰甘油。研究者还测量了静脉输注葡萄糖后胰岛素反应和肝脏的胰岛素敏感性,以及使用半固体测试餐后血

CDS 2015:ORBIT研究启示

中国口服药控制不佳时的2型糖尿病患者起始基础胰岛素治疗的观察性注册研究(ORBIT研究)是为了评价中国不同级别医院基础胰岛素起始治疗的现状,以及不同基础胰岛素治疗方案的应用、对血糖控制以及安全性之间的区别。研究设计:8个地区的200家医院,20000名口服降糖药治疗失效的2型糖尿病患者(HbAlc>7%),在起始基础胰岛素治疗后6个月时间中进行3次随访,每次随访时收集详细的胰岛素治疗信息。入